JP2007503384A5 - - Google Patents

Download PDF

Info

Publication number
JP2007503384A5
JP2007503384A5 JP2006523699A JP2006523699A JP2007503384A5 JP 2007503384 A5 JP2007503384 A5 JP 2007503384A5 JP 2006523699 A JP2006523699 A JP 2006523699A JP 2006523699 A JP2006523699 A JP 2006523699A JP 2007503384 A5 JP2007503384 A5 JP 2007503384A5
Authority
JP
Japan
Prior art keywords
methyl
triene
methano
pyrido
hexahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006523699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007503384A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/002604 external-priority patent/WO2005018622A1/en
Publication of JP2007503384A publication Critical patent/JP2007503384A/ja
Publication of JP2007503384A5 publication Critical patent/JP2007503384A5/ja
Abandoned legal-status Critical Current

Links

JP2006523699A 2003-08-22 2004-08-09 肥満症の治療又は体重減量を容易にする若しくは促進するための医薬組成物 Abandoned JP2007503384A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49735303P 2003-08-22 2003-08-22
PCT/IB2004/002604 WO2005018622A1 (en) 2003-08-22 2004-08-09 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss

Publications (2)

Publication Number Publication Date
JP2007503384A JP2007503384A (ja) 2007-02-22
JP2007503384A5 true JP2007503384A5 (enExample) 2007-09-13

Family

ID=34216115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523699A Abandoned JP2007503384A (ja) 2003-08-22 2004-08-09 肥満症の治療又は体重減量を容易にする若しくは促進するための医薬組成物

Country Status (7)

Country Link
US (1) US20050043406A1 (enExample)
EP (1) EP1658059A1 (enExample)
JP (1) JP2007503384A (enExample)
BR (1) BRPI0413670A (enExample)
CA (1) CA2534271A1 (enExample)
MX (1) MXPA06002049A (enExample)
WO (1) WO2005018622A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000806A2 (en) * 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
EP1670452A2 (en) * 2003-09-25 2006-06-21 Warner-Lambert Company LLC Method of use of aminoacids having affinity for the a2d protein
KR100768974B1 (ko) * 2003-09-25 2007-10-22 워너-램버트 캄파니 엘엘씨 알파2델타-단백질에 대한 친화성을 갖는 아미노산
WO2007115092A2 (en) * 2006-03-29 2007-10-11 Georgetown University 10-substituted cytisine derivatives and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001840T2 (tr) * 1997-12-31 2000-12-21 Pfizer Products Inc. Arile bağlı azopolisiklik bileşikler
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands

Similar Documents

Publication Publication Date Title
AU2007247480B8 (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
JP2010535802A5 (enExample)
CN100430048C (zh) 治疗下泌尿道症状的α-2-δ配体
US20050288375A1 (en) Method and composition for treating neurodegenerative disorders
US20050059654A1 (en) Method for treatment of depression and anxiety disorders by combination therapy
JP2011168606A (ja) 下部尿路症状を治療するα−2−δリガンド
AU2006212772A1 (en) Combination of organic compounds
US7012098B2 (en) Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
JP2007503384A5 (enExample)
JP6116674B2 (ja) (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ−[3,4,b]インドール]−4−アミンおよびプロピオン酸誘導体を含む医薬組成物
US20100063009A1 (en) Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1.3-diol and an NSAID
US20060079579A1 (en) Combinations of valsartan with cox-2 inhibitors
AU2003303040B2 (en) Pregabalin derivatives for the treatment of fibromyalgia and other disorders
RU2007131934A (ru) Применение 2-(2-нитро-4-трифторметилбензоил)-1,3-циклогександиона при лечении болезни паркенсона
US20050043406A1 (en) Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043407A1 (en) Pharmaceutical composition for the prevention and treatment of addiction in a mammal
MXPA06002024A (es) Composicion farmaceutica que comprende un ligando alfa2delta y un antagonista del receptor opioide para la prevencion y el tratamiento de la adiccion en un mamifero.
EP1827495B1 (fr) Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
JP2007508242A (ja) トロンボキサンa2受容体アンタゴニストとシクロオキシゲネーゼ−1の阻害剤との組み合わせを伴う組成物および方法